Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Topics : Radiotherapy and physical agents
  • Topics : Skin and connective tissue diseases
  • Topics : Respiratory tract cancers
  • Topics : Respiratory tract diseases
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
    • Radiotherapy and physical agents (1)
  • Diseases and conditions (1)
  • Plus ...
    • Respiratory tract diseases (1)
    • Plus ...
      • Respiratory tract cancers (1)
    • Digestive system diseases (1)
    • Plus ...
      • Digestive system cancers (1)
    • Skin and connective tissue diseases (1)
    • Plus ...
      • Skin and connective tissue cancers (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Language
  • Français (1)

Drugs, devices and medical acts - 1 result

  • ERBITUX (cetuximab)

    Medicine - Posted on 8/1/2016 - Mis à jour le 12/6/2019
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
aZMcjuS8xYzzjLuR